From the preclinical data of Aggen et al., it was reported that anti-IL1β monotherapy or combination therapy with anti-IL1β plus anti-PD-1/cabozantinib inhibited tumor growth significantly in a renal cell carcinoma model through decreasing immunosuppressive myeloid-derived suppressor cells and increasing M1-TAMs in TME (63). The gene discussed is IL1B; the disease is hereditary clear cell renal cell carcinoma.